Nasdaq 100 Stocks SEC Filings — October 02, 2026

Q3 2026 deliveries of 486,532 vehicles exceeded production of 464,391 by 4.8%, indicating strong demand absorption. Energy storage deployments hit 13.7 GWh, a key growth driver. Full financial results on Oct 21 are a major catalyst.

Eight directors were awarded ~921 NQSOs each, and the CAO received 1,075 options. This is a routine annual grant but signals board-level alignment with long-term shareholder value creation.

Five directors received stock awards (920 to 2,011 shares each), including Director Honickman who now holds 278,627 shares. Consistent director compensation reflects stable governance.

Filed an S-3 for 25M shares held by Amazon.com NV Investment Holdings. Qualcomm gets no proceeds, and the shares stem from a prior warrant exercise—no new dilution or capital raise.

CEO Daniel O'Day sold 15,000 shares (~$2.2M) under a 10b5-1 plan. While pre-planned, the size and timing near $148 suggest a lack of near-term bullish catalyst.

Director Frances Arnold sold 83 shares (~$28K) under a 10b5-1 plan. A very small sale, likely for tax or diversification purposes, not a material signal.

CEO Michael Intrator sold 78,552 shares ($6.89M), CDO Brannin sold 56,531 ($4.96M), and CSO Venturo sold 65,616 ($5.75M)—a combined $17.6M insider liquidation at ~$87.69. This is a massive red flag for a recently public AI infrastructure company.

Director Swan received 38 RSUs, while Directors Liu and Bjorlin each got 29 shares. Small grants, but Swan's RSUs suggest board-level retention incentives.

SVP/CAO Patricia Grech sold 98 shares (~$18.3K) under a 10b5-1 plan. De minimis sale, no signal.

CEO, CDO, and CSO sold a combined $17.6M in a single day at $87.69. For a company that went public recently, this coordinated top-level selling suggests insiders see limited upside or want to lock in gains before potential volatility.

CEO O'Day sold $2.2M worth of stock at ~$148. While under a 10b5-1 plan, the sale represents ~2.6% of his holdings and comes as biotech faces patent cliff and pipeline uncertainty.

All three CoreWeave insiders sold at exactly $87.69, suggesting a pre-arranged program. The uniformity of price and timing amplifies the risk of a coordinated exit.

The registration of 25M shares for Amazon could overhang the stock if Amazon decides to sell aggressively. While not a company risk, it creates a potential supply overhang.

The 921 NQSOs awarded to each director are standard, but the lack of any insider buying alongside the grants means no bullish vote of confidence from the board.

Frances Arnold's sale, while small, is part of a broader pattern of insider selling at Alphabet. No insider buying was reported in this batch.

486,532 deliveries vs. 464,391 produced signals strong demand. Energy storage at 13.7 GWh is a high-margin growth lever. Ahead of Oct 21 earnings, this is a near-term catalyst.

Eight directors and the CAO receiving options creates alignment with shareholders. Netflix's content and ad-tier strategy could drive upside; the option grants suggest the board is incentivized for long-term performance.

The S-3 is for a selling stockholder (Amazon), not a new share issuance. Qualcomm's core business remains strong with mobile and IoT tailwinds. The filing removes uncertainty around the warrant shares.

Director stock awards (1,552 shares each to most) reflect a stable board. Comcast's cash flow and broadband/streaming assets provide a defensive play in a volatile market.

Director Swan's 38 RSUs indicate the board is focused on retention. With memory cycle recovery and AI-driven demand, Micron could see upside as HBM3e ramps.

The CEO's sale was pre-planned. If the stock dips on this news, it could be a buying opportunity for a biotech with a strong HIV franchise and pipeline catalysts (e.g., lenacapavir).

CoreWeave's top three executives sold $17.6M in a single day, contrasting with the routine director grants at Netflix and Comcast. This signals that early-stage AI infrastructure companies may be facing insider skepticism on valuation or growth sustainability.

20 of 31 filings were director stock/option awards (Netflix, Comcast, Micron). This is a governance maintenance theme—no bullish or bearish signal, but it underscores the importance of separating routine grants from opportunistic insider trades.

Tesla's Q3 delivery and production data was the only operational update in this batch. Its beat on deliveries and energy storage growth provides a positive data point for the EV/solar sector ahead of earnings season.

This batch lacked income statement or balance sheet filings (10-K, 10-Q). The insights are limited to insider activity and operational metrics. Investors should watch for upcoming 10-Qs to assess revenue/margin trends across the index.

Gilead's CEO sale, while pre-planned, adds to a pattern of insider selling in large-cap biotech. Investors should monitor upcoming pipeline data and patent cliff strategies for Gilead and peers.

Full financial results on Oct 21, 2026. Watch for automotive gross margin, energy storage profitability, and Cybertruck ramp commentary. Delivery beat suggests upside potential.

After $17.6M in insider sales, monitor for additional Form 4 filings. If more insiders sell, it could signal deeper issues with the AI cloud business model.

CEO sold $2.2M; watch for any changes in guidance or pipeline setbacks at upcoming investor events. The HIV and oncology pipeline is key.

The S-3 registers 25M shares for Amazon. Monitor for any Form 4 filings from Amazon indicating a sale, which could pressure Qualcomm's stock.

With director options granted, watch for Q3 subscriber numbers and ad-tier adoption. The options suggest the board is focused on long-term value.

Director RSUs suggest retention. Watch for HBM3e revenue contribution and DRAM pricing trends in upcoming earnings.

Director awards signal stability. Watch for broadband subscriber trends and Peacock profitability in Q3 earnings.